THYMIDINE FOR PREVENTING NEURAL TUBE DEFECTS
    31.
    发明申请
    THYMIDINE FOR PREVENTING NEURAL TUBE DEFECTS 审中-公开
    用于预防神经管缺陷的THYMIDINE

    公开(公告)号:US20150352137A1

    公开(公告)日:2015-12-10

    申请号:US14410530

    申请日:2013-06-21

    申请人: UCL Business PLC

    摘要: The present invention relates to the prevention of neural tube defects. In particular, the invention provides thymidine or dTMP for use in a method of preventing or prophylactically treating a neural tube defect. The method may comprise administering the thymidine or dTMP to a female mammal that is pregnant or that may become pregnant. The thymidine or dTMP may be administered in combination with one or more purine molecules.

    摘要翻译: 本发明涉及神经管缺陷的预防。 特别地,本发明提供了用于预防或预防性治疗神经管缺陷的方法中的胸苷或dTMP。 该方法可以包括对怀孕或可能怀孕的雌性哺乳动物施用胸苷或dTMP。 胸苷或dTMP可以与一种或多种嘌呤分子组合施用。

    COMPOSITION
    36.
    发明申请
    COMPOSITION 审中-公开
    组成

    公开(公告)号:US20140371106A1

    公开(公告)日:2014-12-18

    申请号:US14367391

    申请日:2012-12-21

    申请人: UCL BUSINESS PLC

    摘要: The invention provides light-emitting compositions, including lasing and fluorescent compositions. The invention particularly relates to programmable biological substrates, which fluoresce and/or lase, and which have a wide variety of different applications. The invention extends to use of the fluorescent compositions and lasing compositions comprising programmable biological substrates in fabricating lasers, and in various biological imaging applications, such as in assays.

    摘要翻译: 本发明提供发光组合物,包括激光和荧光组合物。 本发明特别涉及可发荧光和/或发光并且具有多种不同应用的可编程生物底物。 本发明延伸到使用荧光组合物和包含可编程生物底物的激光组合物在制造激光器以及各种生物成像应用中,例如在测定中。

    METHOD FOR OBTAINING MAB-LIKE CELLS AND USES THEREOF
    37.
    发明申请
    METHOD FOR OBTAINING MAB-LIKE CELLS AND USES THEREOF 审中-公开
    用于获得MAB样细胞的方法及其用途

    公开(公告)号:US20140363405A1

    公开(公告)日:2014-12-11

    申请号:US14373399

    申请日:2013-01-18

    申请人: UCL Business PLC

    IPC分类号: A61K35/54

    摘要: The invention relates to the derivation of mesoangioblast-like (MAB-like) cells from pluripotent cells such as induced pluripotent (IPS) and embryonic stem (ES) cells, to cells obtained thereby and to medical uses of such cells, in particular in the treatment of muscular dystrophies.

    摘要翻译: 本发明涉及从诸如诱导多能(IPS)和胚胎干细胞(ES)细胞的多能细胞衍生的成细胞样细胞(MAB样细胞)到由此得到的细胞以及这种细胞的医学用途,特别是在 治疗肌营养不良症。

    DETECTION AND TREATMENT OF BREAST CANCER
    38.
    发明申请
    DETECTION AND TREATMENT OF BREAST CANCER 审中-公开
    乳腺癌的检测与治疗

    公开(公告)号:US20140349931A1

    公开(公告)日:2014-11-27

    申请号:US14366878

    申请日:2012-12-20

    摘要: The present invention describes methods for determining the risk that a breast precursor lesion will progress to invasive breast cancer and/or the risk of recurrent non-invasive disease in a patient, comprising detecting the presence and/or level of PAPPA and/or PAPPA functional activity in a breast tissue sample obtained from the patient, wherein if PAPPA is not present, or is present at a reduced amount compared to a control, there is the risk of progression to invasive cancer and/or the risk or recurrent disease.The present invention also enables the chemosensitisation of mitotically delayed breast cancer cells to anti-proliferative agents, preferably anti-mitotic agents, by restoring normal progression through mitosis. In this embodiment a first drug is applied to release breast cancer cells from the mitotic block and, sequentially, a second drug affecting proliferating cells is administered for cancer cell killing.

    摘要翻译: 本发明描述了用于确定乳腺前体病变将进入侵袭性乳腺癌的风险和/或患者中复发性非侵入性疾病的风险的方法,包括检测PAPPA和/或PAPPA功能的存在和/或水平 从患者获得的乳腺组织样品中的活性,其中如果PAPPA不存在或者以与对照相比减少的量存在,则存在进展为侵袭性癌症和/或风险或复发性疾病的风险。 本发明还通过恢复通过有丝分裂的正常进展,使得有丝分裂延迟的乳腺癌细胞对抗增殖剂(优选抗有丝分裂剂)的化学增敏作用。 在该实施方案中,施用第一种药物以从有丝分裂块释放乳腺癌细胞,并且依次施用影响增殖细胞的第二种药物用于癌细胞杀伤。